Clinical Trials Logo

Unresectable Pancreatic Cancer clinical trials

View clinical trials related to Unresectable Pancreatic Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03138720 Active, not recruiting - Clinical trials for Pancreatic Adenocarcinoma

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

Start date: May 23, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.

NCT ID: NCT02041936 Active, not recruiting - Clinical trials for Unresectable Pancreatic Cancer

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System

Start date: April 2014
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the short and intermediate term outcomes of the NanoKnife Irreversible Electroporation System when used to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating symptoms of unresectable pancreatic cancer. The NanoKnife, System has been commercially available since 2009, and is FDA-approved to treat soft tissue tumors. The NanoKnife System has received FDA clearance for the surgical ablation of soft tissue. It has not received clearance for the therapy or treatment of any specific disease or condition. Irreversible electroporation (IRE) has the potential to dramatically widen the treatment options for patients with pancreatic cancer. It provides a minimally invasive procedure that could potentially avoid radical surgery for smaller lesions, and it could potentially offer palliation of symptoms such as pain, gastric outlet obstruction and jaundice in patients with locally advanced unresectable disease.

NCT ID: NCT01972919 Active, not recruiting - Clinical trials for Unresectable Pancreatic Cancer

Magnetic Resonance (MR) Guided, Dose-Escalated Radiation Therapy (RT) + Chemotherapy in Pancreatic Cancer

Start date: December 10, 2015
Phase: Phase 2
Study type: Interventional

This research study is for people who have pancreas cancer for which surgery is not recommended. Potential patients must have already received several months of chemotherapy before they are eligible for this study and there will not have been any detectable spread of their tumor on imaging studies following this chemotherapy course.